The triangle report also only values one aspect of Bisantrene...

The triangle report also only values one aspect of Bisantrene for the US only.

Not included in the triangle report is it's use as an FTO inhibitor, which is cutting edge science that can allow it to not only treat dozens of cancers but other indications like diabetes, ect. This has the propensity to double Krons conservative figures as FTO would easily, equally be as big as breast cardio protect.

AML, our pathway to approval was also not included in the triangle report.

It has been expressed by others, including the largest SH that these different indications could be sold off separately. Although harder to do, with quick flick Dr John C now out the door, anything can happen.

Agree with some other posts that following the new revised strategy we need some news momentum. Dominisini data, RC200, Naglar presenting at ASH and a full time CEO aligned with the vision to create max value for SHs.

One concern is Pete is only meant to be giving Race 40% of his time or basically two days a week. I hope Mary and Pete are working day and night to rectify the previous issues and are working in the best interests of SHs.